Literature DB >> 2742164

Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers.

T H Stanley1, B Hague, D L Mock, J B Streisand, S Bubbers, R R Dzelzkalns, P L Bailey, N L Pace, K A East, M A Ashburn.   

Abstract

The authors determined whether fentanyl incorporated into a candy lollipop, oral transmucosal fentanyl citrate (OTFC), would cross mucosal tissues of the mouth in sufficient quantities during and after dissolution to produce sedation and/or analgesia. Associated respiratory and circulatory changes, side effects, and plasma concentrations of fentanyl were also measured. The evaluations were done in 28 adult volunteers who received fentanyl citrate in doses of 5, 4, 2, 1, and 0.5 mg in OTFC and rapidly sucked the lollipops (N = 20) or allowed them to passively dissolve (N = 8). Rapid consumption of OTFC resulted in more rapid onset of a pleasant feeling (first subjective sensation) but not more rapid onset of objective sedation or analgesia than passive dissolution. There was a significant correlation between dose of OTFC and magnitude of sedation (P less than 0.001, Spearman rank correlation = -0.82). Higher doses of OTFC produced greater and longer lasting analgesia and respiratory depression and a higher incidence of nausea and vomiting than lower doses, but pruritus (33%-87%) was not related to the dose of OTFC. Heart rate and arterial blood pressures were not changed by any dose of OTFC. The data indicate that low doses of OTFC (0.5 and 1 mg, equivalent to 5-20 micrograms.kg-1 of fentanyl citrate) produce analgesia and sedation with minimal side effects and little respiratory depression in adult volunteers and deserve further evaluation in patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2742164

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Anesthesia for the 21st century.

Authors:  T H Stanley
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

Review 2.  Oral transmucosal fentanyl. Help or hindrance?

Authors:  M A Ashburn; J B Streisand
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

3.  Oral transmucosal fentanyl citrate for premedication in paediatric outpatients.

Authors:  M A Ashburn; J B Streisand; S D Tarver; S L Mears; S M Mulder; A W Floet Wilms; R W Luijendijk; R A Elwyn; N L Pace; T H Stanley
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

4.  [Analgesia with opioids in the paediatric patient.].

Authors:  C Schlünder
Journal:  Schmerz       Date:  1992-12       Impact factor: 1.107

5.  [New modes of opioid administration.].

Authors:  H W Striebel; R Schwagmeier; N Boerger
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

6.  [Drug therapy for tumor pain I. Properties of non-opioids and opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

7.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

8.  Efficacy of Oral Transmucosal Fentanyl Citrate for Premedication in Patients for Surgery under General Anesthesia.

Authors:  Raj Bahadur Singh; Sanjay Choubey; Ria Mehra
Journal:  Anesth Essays Res       Date:  2017 Oct-Dec

9.  Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain.

Authors:  Eric Prommer; Brandy Ficek
Journal:  Patient Prefer Adherence       Date:  2012-06-25       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.